| |
GDKD
|
CIViC
|
TARGET
|
|---|
|
Number of genes
|
170
|
290
|
135
|
|
Number of predictive genes
|
Total
|
170
|
213
|
111
|
|
Exclusive
|
46
|
105
|
10
|
|
Common
|
79
|
|
Number of variant–drug associations
|
618
|
1931
|
111
|
|
Number of cancer types
|
65
|
177
|
Not specified
|
|
Biomarker types
|
Predictive
|
Predictive
|
Predictive
|
|
Prognostic
|
Prognostic
|
|
Diagnostic
|
Diagnostic
|
|
Clinical significance levels
|
Response
|
Sensitivity
|
Free text
|
|
Sensitivity
|
Resistance or non-response
|
|
Increased benefit
|
|
No response
|
|
No sensitivity
|
|
Reduced/decreased sensitivity
|
|
Resistance
|
|
Evidence levels
|
NCCN/FDA
|
A: clinical routine
|
None
|
|
Late trials
|
B: clinical trials
|
|
Early trials
|
C: case reports
|
|
Case report
|
D: preclinical
|
|
Preclinical
|
E: inferential
|
|
Variant specific
|
Yes
|
Yes
|
No
|
|
References provided
|
Yes
|
Yes
|
No
|
|
Version
|
v19
|
1 June 2017
|
v3
|
|
Source
|
[20]
|
[21]
|
[12]
|
- Each column summarizes the specificities of each database: GDKD Gene Drug Knowledge Database, CIViC Clinical Interpretation of Variants in Cancer, TARGET Tumor Alterations Relevant for Genomics-driven Therapy
